The Ohio State University

COVINGTON, Ky., Oct. 31, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat advanced solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), today announced the publication of first-in-human data from a Phase 1 study of BXQ-350 in Clinical Cancer Research, an American Association of Clinical Research (AACR) journal. The study showed that BXQ-350 was well-tolerated with no dose-limiting toxicities. BXQ-350 is currently being studied for the first line treatment of metastatic colorectal cancer (mCRC). "These data provide a large body of work on the use of BXQ-350 in patients," said Robert Wesolowski, MD, Clinical Professor of Internal Medicine at the James Cancer hospital and the Ohio State University Comprehensive Cancer Center. "In a population with such advanced disease, the fact that two patients are alive without disease progression seven years after initiating BXQ-350 treatment is remarkable." The publication highlights adverse event and efficacy data, including multiple patients who survived more than six months without disease progression. The study enrolled 86 patients across over 20 different tumor types, including advanced metastatic disease and high-grade glioma. Preliminary PK data showed that BXQ-350 exhibited linear exposure, crossing the blood–brain barrier and accumulating in relevant tissues. "We are excited to have our Phase 1 monotherapy data published in Clinical Cancer Research," said Jim Beach, CEO and President of Bexion Pharmaceuticals. "These data demonstrate the safety and tolerability of BXQ-350 in a large population with advanced solid tumor disease and high-grade glioma. We are now generating data on the use of BXQ-350 in metastatic colorectal cancer." The Phase 1b/2 trial (ASIST study; NCT05322590) is currently underway evaluating BXQ-350 in combination with the standard of care in newly diagnosed patients with mCRC. About BXQ-350 Bexion's lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional, sphingolipid activator protein, Saposin C, and a phospholipid. Clinically, two Phase 1 clinical trials, one in adults and one in pediatric DIPG patients, have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in solid tumor patients treated with oxaliplatin and other chemo-toxic agents, as well as other neurological diseases. About Bexion Pharmaceuticals Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion has generated data in multiple classes of solid tumors, including high-grade gliomas, pediatric brain tumors, and colorectal cancer. The Company has also competed enrollment in a proof-of-concept trial for the treatment of CIPN. The Phase 1b/2 study in mCRC is enrolling patients in the open label portion of the study. Investor Contact: William Windham Solebury Strategic Communications 646-378-2946 [email protected] Media Contact: Joyce LaViscount Bexion Pharmaceuticals 859-446-7386 [email protected] SOURCE Bexion Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Merit Awards recognize mental health leader with top honors in healthcare category for its impact on student mental health NATICK, Mass., Oct. 31, 2024 /PRNewswire/ -- Uwill, the leading mental health and wellness solution for colleges and students, was honored as the 2024 Merit Awards for Healthcare 'Gold' winner for 'Best Mental Health Technology'. "The 2024 Healthcare winners represent the absolute best in healthcare innovation," said Marie Zander, Executive Director of the Merit Awards. "These pioneers are setting a high bar for the future of healthcare, and we are honored to recognize their exceptional contributions." The Merit Awards Healthcare program honors organizations that have made significant contributions to healthcare across a range of categories. The winners were selected by a distinguished panel of industry experts for their remarkable achievements in improving healthcare delivery and innovation. "Our team is honored to receive this award, which underscores our commitment to offering immediate mental health and wellness support, eliminating all barriers to care," said Michael London, Founder and CEO of Uwill. "We're dedicated to meeting the mental health needs of all students. This award reflects the positive impact our technology and our counselor community have made on campuses nationwide." Utilizing its proprietary technology and counselor team, Uwill pioneered the first student and therapist matching platform. The solution offers an immediate appointment with a licensed counselor based on student preferences, all modalities of teletherapy, a direct crisis connection, wellness events, realtime data, and support. Uwill serves more than 3 million students from all 50 states at institutions including Rutgers University, the Alabama Community College System, Morgan State University, and University of California, Santa Barbara. About Uwill: Uwill is the leading mental health and wellness solution for colleges and students, and the 27th fastest growing private company in the nation. As the most cost-effective way to enhance a college's mental health offering, Uwill partners with more than 400 institutions, including Princeton University, the Ohio State University, Santa Fe Community College, and University of Alabama - Online. Uwill is also the exclusive teletherapy education partner for the Online Learning Consortium and teletherapy education partner of NASPA. For more information, visit uwill.com. Contact: Brett Silk [email protected] SOURCE Uwill, Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Veris Health, a subsidiary of PAVmed, has been awarded a $1.8 million grant from the National Institute on Minority Health and Health Disparities, part of the National Institutes of Health (NIH). The aim of the two-year grant is to fund research and upgrade and verify the Veris cancer care platform designed for medically underserved patients with cancer. PAVmed is a medical technology company in the medical device, diagnostics and digital health space. Veris Health's main product is the Veris cancer care platform. The research project, "Bridging the Gap: Enhancing Cancer Care for Underserved Populations with the Veris Health Cancer Care Platform," will center on patients with language barriers and narrow access to technology and socioeconomic inequality. "We are honored to receive this prestigious NIH grant, which recognizes the potential of our Veris Cancer Care Platform to enhance cancer care," Dr. James D. Mitchell, PAVmed's vice president of digital health and Veris's chief medical officer, said in a statement. "This grant will accelerate our efforts to expand the reach and impact of our technology, while strengthening our relationships with academic cancer centers and within the oncology community. We look forward to bringing the benefits of this technology to broader and more diverse patient populations, to improve patient outcomes, reduce healthcare costs, and increase patient access to enhanced cancer care." Dr. Lishan Aklog, PAVmed's chairman and chief executive officer, said the NIH grant provides Veris with important non-dilutive funding and comes at a pivotal time for Veris as it pursues financing to advance its commercial strategy, which includes the regulatory clearance and launch of its implantable physiological monitor. "This aligns with PAVmed's long-term strategy, which seeks to assure that its subsidiaries, such as Veris, are independently financeable but able to leverage PAVmed's shared infrastructure," Aklog said in a statement. THE LARGER TREND In September, PAVmed announced that, as part of an effort to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics would be deconsolidated from PAVmed's financial statements; therefore, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remained unchanged and the value of the holdings will be reported going forward as an asset on its balance sheet. In June, PAVmed, announced that its subsidiary, Veris, had launched a pilot program with the Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and enrolled the first patients on the Veris Cancer care platform.